A critical review of which children with acute myeloid leukaemia need stem cell procedures

No abstract is available for this paper.

• Publication year

  2014

• Venue

  British Journal of Haematology

• Publication date

  2014-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjh.12900PMID 24749666
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.

  2014cited by this paper
• t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients

  2014cited by this paper
• Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

  2014cited by this paper
• Comparable survival for pediatric acute myeloid leukemia with poor‐risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation

  2014cited by this paper
• Umbilical cord blood transplantation: the first 25 years and beyond.

  2013cited by this paper
• Pubertal development and fertility in survivors of childhood acute myeloid leukemia treated with chemotherapy only: A NOPHO‐AML study

  2013cited by this paper
• Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients

  2013cited by this paper
• Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies

  2013cited by this paper
• Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia.

  2013cited by this paper
• Allo-SCT using BU, CY and melphalan for children with AML in second CR

  2013cited by this paper
• Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.

  2013cited by this paper
• Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.

  2013cited by this paper
• Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

  2013cited by this paper
• Genetic profiling in acute myeloid leukaemia ─ where are we and what is its role in patient management

  2013cited by this paper
• Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.

  2013cited by this paper
• The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.

  2013cited by this paper
• NUP98‐NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia

  2013cited by this paper
• Prognostic significance of flow cytometric minimal residual disease assessment after the first induction course in Chinese childhood acute myeloid leukemia.

  2013cited by this paper
• Reduced-intensity conditioning followed by allogeneic transplantation in pediatric malignancies: a report from the Société Française des Cancers de l’Enfant and the Société Française de Greffe de Moelle et de Thérapie Cellulaire

  2013cited by this paper
• Late effects of total body irradiation and hematopoietic stem cell transplant in children under 3 years of age

  2013cited by this paper
• Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia.

  2013cited by this paper
• PBSCT is associated with poorer survival and increased chronic GvHD than BMT in Japanese paediatric patients with acute leukaemia and an HLA‐matched sibling donor

  2013cited by this paper
• Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.

  2013cited by this paper
• Outcome of pediatric patients with acute myeloid leukemia (AML) and −5/5q− abnormalities from five pediatric AML treatment protocols: A report from the Children's Oncology Group

  2013cited by this paper
• Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.

  2012cited by this paper
• Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

  2012cited by this paper
• Antifungal prophylaxis in pediatric hematology/oncology: New choices & new data

  2012cited by this paper
• Metabolic syndrome and endocrine dysfunctions after HSCT in children

  2012cited by this paper
• Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

  2012cited by this paper
• Outcome of Pediatric Patients with Acute Myeloid Leukemia and -5/5q-Abnormalities Enrolled On Five Children's Oncology Group Acute Myeloid Leukemia Treatment Protocols

  2012cited by this paper
• National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines.

  2012cited by this paper
• Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel.

  2012cited by this paper
• Outcome of poor response paediatric AML using early SCT

  2012cited by this paper
• Haploidentical stem cell transplantation for children with high‐risk leukemia

  2012cited by this paper
• NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: health-related quality of life, functional, and neurocognitive outcomes.

  2012cited by this paper
• The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study

  2012cited by this paper
• The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

  2012influential reference
• Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

  2012cited by this paper
• Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

  2012cited by this paper
• Treatment‐related deaths in second complete remission in childhood acute myeloid leukaemia

  2011cited by this paper
• Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.

  2011cited by this paper
• Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS).

  2011cited by this paper
• Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004.

  2011cited by this paper
• Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: A NOPHO‐AML study

  2011cited by this paper
• Presence of FLT 3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia *

  2011cited by this paper
• High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.

  2011cited by this paper
• NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.

  2011cited by this paper
• Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate.

  2011cited by this paper
• Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation.

  2011cited by this paper
• Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms

  2011cited by this paper
• Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: Retrospective cohort study in a single centre in the United Kingdom

  2011cited by this paper
• Long term survival in children with acute leukaemia and complications requiring mechanical ventilation

  2011cited by this paper
• Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial

  2011cited by this paper
• Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.

  2011cited by this paper
• Assessment of minimal residual disease in acute myeloid leukemia

  2010cited by this paper
• Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

  2010cited by this paper
• Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.

  2010cited by this paper
• Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials

  2010cited by this paper
• Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

  2010cited by this paper
• Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience

  2010cited by this paper
• A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia.

  2010cited by this paper
• High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study

  2010cited by this paper
• Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors.

  2010cited by this paper
• Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

  2010cited by this paper
• Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

  2010cited by this paper
• Comparable outcomes of HLA‐matched unrelated and HLA‐identical sibling donor bone marrow transplantation for childhood acute myeloid leukemia in first remission

  2009cited by this paper
• Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML

  2009cited by this paper
• High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event‐free survival

  2009cited by this paper
• Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.

  2009cited by this paper
• Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.

  2009cited by this paper
• Management of relapse after allo-SCT for AML and the role of second transplantation

  2009cited by this paper
• Twenty years of follow‐up among survivors of childhood and young adult acute myeloid leukemia

  2008cited by this paper
• Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population

  2008cited by this paper
• Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only?

  2008cited by this paper
• Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals

  2008cited by this paper
• Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy.

  2008cited by this paper
• Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group.

  2008cited by this paper
• Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study.

  2007cited by this paper
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007cited by this paper
• Pediatric acute myeloid leukemia: towards high-quality cure of all patients

  2007cited by this paper
• Improved outcome after relapse in children with acute myeloid leukaemia

  2007influential reference
• Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.

  2007cited by this paper
• Twenty Years of Follow-Up among Survivors of Childhood and Young Adult Acute Myeloid Leukemia (AML): A Report from the Childhood Cancer Survivor Study (CCSS).

  2006cited by this paper
• Clinical implications of FLT3 mutations in pediatric AML.

  2006cited by this paper
• Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML.

  2006cited by this paper
• Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit – multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group

  2005cited by this paper
• Long-term results in children with AML: NOPHO-AML Study Group – report of three consecutive trials

  2005influential reference
• Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?

  2005cited by this paper
• Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials

  2005cited by this paper
• Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials

  2005cited by this paper
• Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891

  2005cited by this paper
• Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO‐AML trials

  2003cited by this paper
• New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

  2003cited by this paper
• FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.

  2003cited by this paper
• Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry

  2002cited by this paper
• A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission.

  2001cited by this paper
• Late effects of treatment in survivors of childhood acute myeloid leukemia.

  2000cited by this paper
• Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia.

  1999cited by this paper
• The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

  1998cited by this paper
• Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.

  1997cited by this paper

• Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

  2025cites this paper
• Azacitidine as maintenance therapy in pediatric de novo acute myeloid leukemia

  2025cites this paper
• Prophylactic donor lymphocyte infusions after first allogeneic hematopoietic stem cell transplantation in children with acute leukemia

  2025cites this paper
• The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia

  2025cites this paper
• Comprehensive up-to-date analysis on TCRαβ/CD19-depleted hematopoietic stem cell transplantation in pediatric hematological malignancies.

  2025cites this paper
• Early Allogeneic Transplantation Favorably Influences the Outcome of Pediatric Acute Myeloid Leukemia-A Retrospective Study in a Single Center Over 2 Decades.

  2024cites this paper
• Acute myeloid leukaemia in the Johannesburg public sector: A laboratory-based study

  2024cites this paper
• Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post‐transplant cyclophosphamide for treatment of high‐risk myeloid neoplasms in children: A retrospective study

  2023cites this paper
• Optimizing transplantation procedures through identification of prognostic factors in second remission for children with acute myeloid leukemia with no prior history of transplant

  2023influential citation
• Cardiovascular morbidity following conventional therapy versus allogeneic hematopoietic stem cell transplantation after childhood, adolescent, and young adult leukemia in Finland

  2023cites this paper
• Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

  2022cites this paper
• A call for revision of the World Health Organization classification system to include FLT3-ITD as a distinct entity

  2022cites this paper
• Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios

  2022cites this paper
• Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis

  2022cites this paper
• The outcomes of children with acute myeloid leukemia treated in accordance with the AML–MM-2006 protocol

  2022cites this paper
• Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia.

  2021cites this paper
• Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens

  2021cites this paper
• CEBPA are independent good prognostic factors in pediatric acute myeloid leukemia

  2021influential citation
• The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia

  2021cites this paper
• Wilms’ tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation

  2021cites this paper
• Haploidentical‐ versus identical‐sibling transplant for high‐risk pediatric AML: A multi‐center study

  2020influential citation
• Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia

  2020cites this paper
• Very Late Relapse in Pediatric Acute Myeloid Leukemia: A Case Report and Brief Literature Review

  2020cites this paper
• Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation Compared With Chemotherapy as Postremission Treatment of Children With Intermediate-risk Acute Myeloid Leukemia in First Complete Remission.

  2020cites this paper
• Treatment of Childhood Acute Myeloid Leukemia in Uruguay: Results of 2 Consecutive Protocols Over 20 Years

  2020influential citation
• Clinical characteristics of testicular extramedullary involvement in multiple myeloma

  2020cites this paper
• Hospitalizations in long‐term survivors of childhood AML treated with allogeneic HCT—An Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study

  2020cites this paper
• Haploidentical Stem Cell Transplantation With Post-transplant Cyclophosphamide for Pediatric Acute Leukemia is Safe and Effective

  2020cites this paper
• Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia

  2020cites this paper
• Opportunities for immunotherapy in childhood acute myeloid leukemia.

  2019influential citation
• Response‐guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML‐01

  2019cites this paper
• Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial

  2019cites this paper
• Gonadal failure among female patients after hematopoietic stem cell transplantation for non-malignant diseases

  2019cites this paper
• Treatment of Molecular Relapse by Cessation of Immunosuppression After Hematopoietic Stem Cell Transplantation in Pediatric FLT3-ITD AML Monitored by WT1 Expression in Peripheral Blood.

  2019cites this paper
• Opportunities for immunotherapy in childhood acute myeloid leukemia.

  2019influential citation
• Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019

  2019cites this paper
• Low‐dose azacitidine for relapse prevention after allogeneic hematopoietic cell transplantation in children with myeloid malignancies

  2019cites this paper
• The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children.

  2019cites this paper
• Proteína multifuncional ADE2 como nexo entre vías de recuperación y síntesis de novo de nucleótidos

  2018cites this paper
• Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012

  2018cites this paper
• Acute myeloid leukemia (AML) with t(7;12)(q36;p13) is associated with infancy and trisomy 19: Data from Nordic Society for Pediatric Hematology and Oncology (NOPHO‐AML) and review of the literature

  2018cites this paper
• Complete Remission of a Refractory Acute Myeloid Leukemia with Myelodysplastic- and Monosomy 7-Related Changes after a Combined Conditioning Regimen of Plerixafor, Cytarabine and Melphalan in a 4-Year-Old Boy: A Case Report and Review of Literature

  2018cites this paper
• Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: a NOPHO–AML Study

  2018cites this paper
• Allogeneic hematopoietic cell transplantation in chemotherapy‐induced aplasia in children with high‐risk acute myeloid leukemia or myelodysplasia

  2018cites this paper
• Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia. A NOPHO‐DBH‐AML study

  2018cites this paper
• Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality

  2018cites this paper
• CBFA2T3‐GLIS2‐positive acute myeloid leukaemia. A peculiar paediatric entity

  2018cites this paper
• Indications for Hematopoietic Stem Cell Transplantation in Children

  2018cites this paper
• Estudi del perfil d'expressió de les histones deacetilasa (hdac) en pacients pediàtrics amb leucèmia aguda

  2018cites this paper
• Investigation of cytogenetic markers in neonatal blood spots and of aberrant protein expression in bone marrow from children with leukemia

  2018cites this paper
• Стандарт российско-белорусской кооперативной группы по иммунофенотипированию острого лимфобластного лейкоза у детей

  2018cites this paper
• Current Management of Childhood Acute Myeloid Leukemia

  2017influential citation
• Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia

  2017cites this paper
• Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004

  2017cites this paper
• Caracterització de les alteracions moleculars de FLT3 en pacients pediàtrics afectes de leucèmia aguda. Correlació amb l’activitat i expressió dels transportadors de fàrmacs derivats de nucleòsids

  2017cites this paper
• Strategies for reducing the treatment‐related physical burden of childhood acute myeloid leukaemia – a review

  2017influential citation
• Cytogenetics and outcome of allogeneic transplantation in first remission of acute myeloid leukemia: the French pediatric experience

  2017cites this paper
• FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia

  2016cites this paper
• Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study.

  2016cites this paper
• MYELOID NEOPLASIA Recurrent abnormalities can be used for risk group strati fi cation in pediatric AMKL: a retrospective intergroup study

  2016cites this paper
• Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?

  2016influential citation
• Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy.

  2016cites this paper
• TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia

  2016cites this paper
• Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved Issues

  2016cites this paper
• Novel approaches to pediatric leukemia treatment

  2015cites this paper
• Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.

  2015cites this paper
• Increased p53 protein expression as a potential predictor of early relapse after hematopoietic stem cell transplantation in children with acute myelogenous leukemia

  2015influential citation
• Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study.

  2015cites this paper
• Pediatric AML: From Biology to Clinical Management

  2015cites this paper
• Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015

  2015cites this paper
• High body mass index did not result in poor outcome in Taiwanese children with acute myeloid leukemia: a single-institution experience

  2015cites this paper
• Different aspects of stem cell procedures in children with poor responding AML: when is HSCT the best answer?

  2015cites this paper
• Studies of specific viruses from Guthrie cards and prognostic markers in bone marrow samples from children diagnosed with leukemia

  2014cites this paper